Page 92 - Drug Class Review
P. 92
Page 76 of 205
Drug Effectiveness Review Project
placebo 70 3 5 7 2 3 6 4 6 5 8 6 placebo 17% (54) 5% (15)
galantamine 72 7 14 7 9 5 4 7 6 4 7 6 galantamine 23% (75) 7% (24)
galantamine PRC 79 6 17 5 7 6 8 10 8 5 7 6 Post randomization exclusions: NR Overall loss to follow-up: 197 (20%) Loss to follow-up differential high: No galantamine PRC 21% (68) 9% (28)
Not reported ITT: Yes Yes Yes Yes Good
Final Report Update 1 Authors: Brodaty et al. Year: 2005 ADVERSE EVENTS: Overall adverse effects reported (%) Anorexia • Nausea • Diarrhea • Vomiting • Depression • Injury • Dizziness • Headache • Respiratory tract infection • Urinary tract infection • Fall • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *prim
